

[Daclatasvir](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.4. Antiviral medicines](#) [6.4.4. Antihepatitis medicines](#) [6.4.4.2. Medicines for hepatitis C](#)

[6.4.4.2.1. Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations](#)

ATC codes: [J05AP07](#)

EMLc

Indication

Chronic hepatitis C ICD11 code: [1E91.1](#)

INN

Daclatasvir

Medicine type

Chemical agent

List type

Core

Additional notes

Pangenotypic when used in combination with sofosbuvir.

Formulations

Oral > Solid > tablet: 30 mg (as dihydrochloride) ; 60 mg (as dihydrochloride)

EML status history

First added in 2015 ([TRS 994](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

Medicines within the same pharmacological class can be used

Therapeutic alternatives limitations

Pangenotypic direct-acting antiviral combinations

Therapeutic alternatives limitations for EMLc

Pangenotypic direct-acting antiviral combinations

Patent information

Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org

Read more [about patents](#).

Wikipedia

[Daclatasvir](#)

DrugBank

[Daclatasvir](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to modify the formulation descriptions to better describe the available dosage forms.